Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) have been assigned an average recommendation of “Buy” from the fifteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have issued a buy recommendation on the […]
Data from Up to Six Months of Treatment with Aficamten Show Significant and Sustained Reductions in LVOT Gradients with Improvements in Functional Class,.
Cytokinetics (NASDAQ:CYTK – Get Rating) had its target price increased by investment analysts at Needham & Company LLC from $52.00 to $60.00 in a research note issued to investors on Thursday, The Fly reports. Needham & Company LLC’s target price points to a potential upside of 46.23% from the stock’s previous close. Several other equities […]
Initial Data from REDWOOD-HCM OLE, the Open Label Extension Study of Aficamten, to be Presented at Heart Failure 2022 on May 23, 2022 Continued Launch.
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 10,000 shares of Cytokinetics stock in a transaction on Wednesday, April 20th. The shares were sold at an average price of $37.89, for a total transaction of $378,900.00. Following the completion of the transaction, the chief executive officer now directly owns 409,124 shares of […]